tbuckley/cabot-search huggingface dataset:
369P The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
Authors: H. Goldvaser, I. Kuchuk, R. Yerushalmi, A. Goldshtein, O. Rotem, A. Lotan, A.A. Gabizon, R. Mutai
Journal: Annals of Oncology (2023)
366P Artificial intelligence (AI)-powered assessment of complete and intense human epidermal growth factor receptor 2 (HER2)-positive tumor cell proportion in breast cancer: Predicting fluorescence in situ hybridization (FISH) positivity and response to HER2-targeted therapy
Authors: M. Jung, S-W. Kim, S.G. Song, S.K. Baek, S.I. Cho, S. Shin, S. Kim, H. Song, S. Park, S. Pereira, D. Yoo
Journal: Annals of Oncology (2023)
295P ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients
Authors: R. Spiller, T. Bracht, S. Kaufhold, M. Bauer, T. Lantzsch, V. Hanf, C. Uleer, S. Peschel, J. John, M. Pöhler, J. Buchmann, E. Weigert, K-F. Bürrig, E. Kantelhardt, C. Thomssen, M. Vetter
Journal: Annals of Oncology (2023)
279P Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Authors: T. Martos Cardenas, N. Garcia-Giralt, I. Petit, M. Castro-Henriques Pinto-Machado, M. Martinez García, X. Monzonis Hernandez, J. Albanell Mestres, X. Nogués Solan, S. Servitja Tormo
Journal: Annals of Oncology (2023)
298P Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
Authors: L. Min Ji, B. Seung Ho, S.E. Lee, Y. Kook, S. Moon, J. Kim, M.J. Kim, S.J. Bae, J. Jeong, S.G. Ahn
Journal: Annals of Oncology (2023)
289P Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
Authors: A. Vethencourt, E.M. Trinidad, E. Dorca Duch, A. Petit, M.T. Soler-Monsó, E. Purqueras, M.E. Brizzi, M. Matas Garcia, G. Pérez-Chacón, M. Jimenez, M. Ciscar, A. Stradella, A. Iserte, A. Gumà Martinez, R. Ortega, M.J. Gil, S. Pernas Simon, C. Falo, E. Gonzalez-Suarez
Journal: Annals of Oncology (2023)
297P Prognostic and predictive impact of NOTCH1 in early breast cancer
Authors: J. Engel, V. Wieder, M. Bauer, S. Kaufhold, V. Hanf, C. Uleer, T. Lantzsch, S. Peschel, J. John, M. Pöhler, E. Weigert, K-F. Bürrig, J. Buchmann, E. Kantelhardt, C. Thomssen, M. Vetter
Journal: Annals of Oncology (2023)
283P Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study
Authors: M. De Laurentiis, G. Hoste, X. González Farre, O. Romano, A. Cano Jimenez, F. Beghdad, O. Dialla, M. Zivanov, T. Silovski
Journal: Annals of Oncology (2023)
285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
Authors: S. Morganti, S.E. Kim, Q. Jin, J. Cha, J.E. Zeigler, A.B. Newman, J. Vincuilla, T. Parker, R. Buehler, E.A. Mittendorf, T.A. King, B. Bychkovsky, G. Curigliano, A.H. Partridge, N.U. Lin, J.E. Garber, N. Tayob, S.M. Tolaney, F. Lynce
Journal: Annals of Oncology (2023)
299P Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer
Authors: X. Wang, D. Gacquer, S. Majjaj, M. Rediti, L. Craciun, D. Larsimont, F. Rothé, C. Sotiriou
Journal: Annals of Oncology (2023)
306P Multiplexed immunofluorescence (mIF) to select patients with HER2+ breast cancer (BC) having an excellent outcome without chemotherapy (chemo): A substudy of the PERNETTA trial (SAKK22/10-UCBG-BOOG)
Authors: K. Zaman, S. Tissot, F. Benedetti, D. Dietrich, D. Tarussio, J. Huober, H. Bonnefoi, P. Weder, E. Boven, S. Rusakiewicz, L.E. Kandalaft
Journal: Annals of Oncology (2023)
292P Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Authors: P. Tiberio, M. Gaudio, S. Belloni, C. Benvenuti, F. Jacobs, G. Saltalamacchia, A. Zambelli, A. Santoro, R. De Sanctis
Journal: Annals of Oncology (2023)
286P Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Authors: A. Musolino, O. Serra, B. Pellegrino, C. Tommasi, D. Zanoni, F. Faccini, M. Michiara, P. Sgargi, G. Carrozzi, S. Ferretti, V. Grossi, A. Ravaioli, F. Zamagni, F. Falcini
Journal: Annals of Oncology (2023)
296P Identification of metabolism-related therapeutic targets to improve response to neoadjuvant chemotherapy in early breast cancers
Authors: F. Derouane, C. Van Marcke de Lummen, J. Ambroise, M. Berliere, M.R. Van Bockstal, G. Jerusalem, V. Bours, C. Josse, C. Corbet, F.P. Duhoux
Journal: Annals of Oncology (2023)
301P Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls
Authors: L. Radmilovic Varga, T. Marić, A. Katušić Bojanac, K. Horvatović, M. Popovic, A. Kulić, T. Silovski, M. Sirotkovic-Skerlev, M. Krizic, K. Bulić, H. Silovski, N. Dedic Plavetic
Journal: Annals of Oncology (2023)
290P Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
Authors: A. Gennari, E. Barberis, V. Martini, S. Gobbato, R. Alsati, R. Ben Ayed, V. Rossi, F. D'Avanzo, B. Ruffilli, B. Malagutti, I. Dodaro, E. Gallarotti, L. Galli, R. Boldorini, A. Gambaro, A. Rampi, C. Branni, M. Manfredi
Journal: Annals of Oncology (2023)
284P Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
Authors: V. Wieder, J. Engel, M. Bauer, S. Kaufhold, V. Hanf, C. Uleer, T. Lantzsch, S. Peschel, J. John, M. Pöhler, E. Weigert, K-F. Bürrig, J. Buchmann, E. Kantelhardt, C. Thomssen, M. Vetter
Journal: Annals of Oncology (2023)
291P Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Authors: E. Ferraro, S. Chew Minmin, D. Nemirovsky, Y. Chen, A.V. Barrio, S. Modi, A. Seidman, H. Wen, E. Brogi, M. Robson, C. Dang
Journal: Annals of Oncology (2023)
282P Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Authors: D. Morchón Araujo, A. Olivares Hernandez, L. Figuero Pérez, J. Claros Ampuero, M. García Muñoz, J. Roldán-Ruiz, M.D.C. Garijo Martínez, E. Terán Brage, Á. López Gutiérrez, M. Sancho de Salas, A. Gómez Muñoz, R. Seijas Tamayo, R. Lozano Mejorada, R.A. Marcos Sánchez, E. Fonseca Sánchez, C.A. Rodríguez Sánchez
Journal: Annals of Oncology (2023)
270P Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Authors: S.E. Lee, Y. Kook, B. Seung Ho, S. Moon, J. Kim, M.J. Kim, S.J. Bae, J. Jeong, S.B. Lee, S.G. Ahn
Journal: Annals of Oncology (2023)
272P Primary prevention of bone fractures in patients (pts) with hormone receptor (HR)+ early breast cancer (EBC) during adjuvant hormonal therapy (HT): The predict &amp; prevent project (P&amp;P)
Authors: S. Gori, R. Berardi, A. Zaniboni, T. Prochilo, C. Bighin, F. Puglisi, A. Del Conte, A. Fabi, F. Riccardi, M. Airoldi, A. Chirco, S. Cinieri, L. Orlando, A. Orlandi, M. Verzè, M. Valerio, F. Nicolis
Journal: Annals of Oncology (2023)
275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Authors: F. Schettini, F. Brasó-Maristany, T. Pascual, P. Galván, B. Conte, L. Ghiglione, C. Falato, O. Martínez-Sáez, N. Chic, A.B. Rodriguez, E. Sanfeliu Torres, B. Gonzalez-Farre, M.J. Vidal Losada, B. Adamo, I. Cebrecos, E. Mension, G. Oses, M. Mollá, M. Munoz, A. Prat
Journal: Annals of Oncology (2023)
271P First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Authors: S. Nizzero, T. Appenzeller, L. Briner, R.A. Burian, A. Jizawi, S. Schädelin, C. Raez, S. Muenst-Soystal, T. Vlajnic, E. Obermann, S. Dellas, S. Forte, Z. Marušić, P.D. Ndiaye, P. Oertle, G. Zaugg, M. Loparic, M. Plodinec
Journal: Annals of Oncology (2023)
273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Authors: P. Neven, N. Stahl, M.J. Vidal Losada, M. Martin Jimenez, P.A. Kaufman, N. Harbeck, K. Hunt, S.A. Carter, F.C. Bidard, P. Fasching, P.G. Aftimos, D. Wheatley, E.P. Hamilton, R. Aft, S. Kulkarni, R. Ismail-Khan, C. Karacsonyi, S.T. Estrem, U. Ozbek, E.M. Ciruelos
Journal: Annals of Oncology (2023)
274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Authors: J. O'Shaughnessy, I. Cicin, L. Testa, S.M. Tolaney, J. Huober, V. Guarneri, S.R.D. Johnston, M. Martin Jimenez, P. Rastogi, N. Harbeck, H.S. Rugo, R.J. Wei, V. Andre, A. Shahir, M.P. Goetz
Journal: Annals of Oncology (2023)
259P Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Authors: T. Susiriwatananont, N. Poovorawan, C. Teerapakpinyo, S. Shuangshoti, L. Jarutasnangkul, M. Tumkosit, P. Chattranukulchai, N. Theerasuwipakorn, S. Manasnayakorn, C. Vinayanuwattikun, Y. Vorasettakarnkij, V. Sriuranpong
Journal: Annals of Oncology (2023)
264P Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Authors: S. Abdullaeva, T.Y. Semiglazova, A. Artemyeva, A. Kudaibergenova, V. Semiglazov, P. Krivorotko, V. Semiglazov
Journal: Annals of Oncology (2023)
SPIRAL: integrating and aligning spatially resolved transcriptomics data across different experiments, conditions, and technologies
Authors: Tiantian Guo, Zhiyuan Yuan, Yan Pan, Jiakang Wang, Fengling Chen, Michael Q. Zhang, Xiangyu Li
Journal: Genome biology (2023)

Abstract Properly integrating spatially resolved transcriptomics (SRT) generated from different batches into a unified gene-spatial coordinate system could enable the construction of a comprehensive spatial transcriptome atlas. Here, we propose SPIRAL, consisting of two consecutive modules: SPIRAL-integration, with graph domain adaptation-based data integration, and SPIRAL-alignment, with cluster-aware optimal transport-based coordination alignment. We verify SPIRAL with both synthetic and real SRT datasets. By encoding spatial correlations to gene expressions, SPIRAL-integration surpasses state-of-the-art methods in both batch effect removal and joint spatial domain identification. By aligning spots cluster-wise, SPIRAL-alignment achieves more accurate coordinate alignments than existing methods.
266P Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Authors: F.M. Schipilliti, A. Rizzo, F. Di Costanzo, S. Acquafredda, G. Arpino, F. Puglisi, L. Del Mastro, F. Montemurro, M. De Laurentiis, M. Giuliano
Journal: Annals of Oncology (2023)
262P Pragmatic clinical trial assessing response to neoadjuvant taxotere and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA): First report from the Nigerian breast cancer study group
Authors: A.I. Ntekim, A. Sanni, A.O. Popoola, A.C. Sowunmi, O. Olasehinde, A. Ibraheem, A. Folasire, A. Adeniji-Sofoluwe, T. Olajide, F. Omodele, A. Komolafe, A. Omisore, M. Ajani, A. Daramola, F. Abdulkareem, O. Balogun, T. Karrison, C. Olopade, J. Obafunwa, O. Olopade
Journal: Annals of Oncology (2023)
258P Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Authors: R. Brugés Maya, J.C. Urrego, C. Marrugo, V. Wurcel, A. Khandelwal, J. Singh, M. Huang, A. Haiderali
Journal: Annals of Oncology (2023)
267P Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Authors: F. Canino, M. Barbolini, U.F.F. De Giorgi, L. Gianni, A. Maestri, L. Moscetti, C. Omarini, C. Zamagni, R. Cuoghi Costantini, F. Tamburrano, G. Antonelli, F. Baglio, L. Belluzzi, G. Martinelli, S. Natalizio, O. Ponzoni, M. Dominici, F. Piacentini
Journal: Annals of Oncology (2023)
261P Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Authors: B.L. Rapoport, H. Steel, C-A. Benn, S. Nayler, T. Smit, L. Heyman, None L. Kwofie, A. Theron, N. Hlatswayo, P. Meyer, R. Anderson
Journal: Annals of Oncology (2023)
263P Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Authors: L.W. Rached, M.P. Spotti, C. Baldini, A. Laparra, C.A. Dutertre Remote, M. Sakkal, A. Perret, A.A. Viansone, J.Z. Zeghondy, E. Rassy, C. Bousrih, P. Abdayem, R.M. Khoury Abboud, H.K. El Masri, T. Grinda, S. Moragon Terencio, B. Verret, S. Champiat, B. Pistilli, J.T.M.L. Ribeiro
Journal: Annals of Oncology (2023)
240MO Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
Authors: M.P. Goetz, N. Turner, H. Sasano, C. Arteaga, S. Chandarlapaty, S. Loi, J.S. Reis-Filho, H. Kreipe, N. Harbeck, P. Fasching, C.S. Rubenstein, S. Wijayawardana, M. Muñoz, L.M. Litchfield, S.R.D. Johnston
Journal: Annals of Oncology (2023)
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)
Authors: A. DeMichele, A.S. Clark, L. Bayne, K. Rohn, I. Nivar, P. Wileyto, L. Berry, S. DeLuca, J. Savage, I. Makhlin, T.C. Pan, J. Graves, G. Belka, J. Wang, N. Shih, D. Berry, A. Nayak, M. Feldman, L. Chodosh
Journal: Annals of Oncology (2023)
251P Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
Authors: J.A. García-Sáenz, G. Spera, M.A. Pollán, B. Bermejo, M. Ruiz Borrego, A. Chan, M. Martin Jimenez, A.L. Guerrero Zotano, L. Calvo-Martinez, A. Rodríguez-Lescure, A. Arcusa Lanza, L.I. Chap, J.P. Crown, V. Bee-Munteanu, M. Casas, O. Polonio, D. Slamon
Journal: Annals of Oncology (2023)
243MO Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial
Authors: H.M. Kuerer, G. Rauch, S. Krishnamurthy, E. Diego, W. Yang, Y. Shen, H. Lin, A. Lucci, T. Moseley, D.L. Ramirez, J.A. Mouabbi, J. Boughey, S. Shaitelman, R. White, K. Hunt, M. Mitchell, M. Teshome, H. Johnson, B. Smith, V. Valero
Journal: Annals of Oncology (2023)
246P Phase II study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: Efficacy, safety and biomarker analysis from the neoALTAL trial
Authors: X. Qi, Y. Liang, J. Liu, Q. Shi, K. Zhu, J. Jiang, Y. Zhang
Journal: Annals of Oncology (2023)
245P Neoadjuvant QL1209 (a pertuzumab biosimilar) compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced, HER2-positive, ER(-)/PR(-) breast cancer: A multicenter, randomized, double-blind, equivalence, phase III study
Authors: Z. Shao, J. Zhang, J. Qian, X. Ma, Z. Niu, J. Ou, Q. Mo, J. Sun, X. Li, Q. Wang, Y. Yao, G. Yu, H. Li, D. Chen, H. Zhang, C. Geng, G. Qiao, M. Zhao, B. Zhang, X. Kang
Journal: Annals of Oncology (2023)
254P Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Authors: M.E. Hatzipanagiotou, M. Pigerl, M. Gerken, S. Räpple, V. Zeltner, M. Hetterich, P. Ugocsai, E.C. Inwald, M. Klinkhammer-Schalke, O. Ortmann, S. Seitz
Journal: Annals of Oncology (2023)
238MO Long-term residential and workplace exposure to air pollution and breast cancer risk: A case-control study nested in the French E3N cohort from 1990 to 2011
Authors: B. Fervers, M. Duboeuf, A. Amadou, T. Coudon, L. Grassot, E. Faure, G. Severi, F. Mancini, P. Salizzoni, J. Gulliver, D. Praud
Journal: Annals of Oncology (2023)
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Authors: N. Roussot, G. Constantin, I. Desmoulins, C. Kaderbhai, A. Hennequin, D. Mayeur, S.M. Ilie, L. Arnould, A. Bertaut, J-C. Eymard, C. Jouannaud, A.M. Savoye, G. Yazbek, D. Allouache, C. Delcambre, I. Hrab, C. Levy, C. Segura Djezzer, M. Deblock, S. Ladoire
Journal: Annals of Oncology (2023)
242MO Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies
Authors: F. Miglietta, M.V. Dieci, T. Giarratano, V. Torri, M. Giuliano, F. Zustovich, M. Mion, C. Tondini, E. Bria, M. Franchi, L. Merlini, R. Giannatiempo, D. Russo, V. Fotia, P. Poletti, E. Rota Caremoli, G. Arpino, G. De Salvo, A. Zambelli, V. Guarneri
Journal: Annals of Oncology (2023)
248P Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
Authors: F. Ligorio, G. Fucà, A. Vingiani, F. Iannelli, R. Lobefaro, C. Ferraris, A. Belfiore, G. Scaperrotta, C. Depretto, A. Martinetti, P. Corsetto, G.V. Bianchi, G. Capri, S. Folli, S. Minucci, M. Foiani, M. Pagani, G. Pruneri, F.G.M. De Braud, C. Vernieri
Journal: Annals of Oncology (2023)
253P Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Authors: V. Angelis, E. Scott, C. Gousis, P.E. Hall, K.M. Hawkesford, R. Nijjar, M. Nathan, P. Schmid, M. Phillips
Journal: Annals of Oncology (2023)
281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: A meta-analysis of randomized clinical trials
Authors: V.F.C. Alves, F.C.A. Moraes, G.D.C. Gomes, G.D.O. Almeida, S. Carnevalli, J.N. Priantti, T.M. Madeira, M. Silveira Vilbert, C. Stecca
Journal: Annals of Oncology (2023)
278P Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Authors: D. van Dorst, S.M. Buijs, M.J.H.A. Kruip, R.F.P. van den Akker, K.L. Cheung, R. Porrazzo, E. Oomen-de Hoop, A. Jager, S.L. Koolen, J. Versmissen, J.A.H. Danser, H.H. Versteeg, M.H.A. Bos, R.H. Mathijssen
Journal: Annals of Oncology (2023)
277P Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Authors: G. Schivardi, R. Pedersini, D. Cosentini, P. di Mauro, M. Zamparini, L. Rinaudo, N. Di Meo, A. Delbarba, C. Cappelli, M. Laganà, A. Alberti, M. Baronchelli, G. Guerci, L. Laini, E.L. Simoncini, D. Farina, G. Mazziotti, A. Berruti
Journal: Annals of Oncology (2023)
276P Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Authors: L. Mastrantoni, G. Garufi, E. Di Monte, G. Arcuri, V. Frescura, N. Maliziola, A. Rotondi, G. Giordano, L. Carbognin, A. Fabi, I. Paris, G. Franceschini, A. Orlandi, A. Palazzo, F. Puglisi, M.V. Dieci, M. Milella, G. Scambia, G. Tortora, E. Bria
Journal: Annals of Oncology (2023)
LBA52 A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
Authors: O. Straume, C. Schuster, S. Aziz, K. Davidsen, J. Karlsen, A.J. Rayford, M.I. Siraji, H. Løvendahl Svendsen, L. Reisæter, B.T. Gjertsen, L. Akslen, J. Lorens
Journal: Annals of Oncology (2023)
LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network
Authors: T. Walter, T. Lecomte, J. Hadoux, P. Niccoli, L. Saban-Roche, E. Gaye, R. Guimbaud, M. Baconnier, V. Hautefeuille, C. Do Cao, C. Petorin, O. Hentic Dhome, M. Perrier, T. Aparicio, J-Y. Scoazec, C. Lombard Bohas, S. Bin, V. Hervieu, M. Barritault, L. Gerard
Journal: Annals of Oncology (2023)
LBA92 Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
Authors: L. Paz-Ares, M-J. Ahn, E. Felip, S. Handzhiev, I. Korantzis, H. Izumi, K. Ohashi, M. Majem, J. Wolf, M. Reck, H-D. Hummel, F. Blackhall, A-M.C. Dingemans, T.K. Owonikoko, S.S. Ramalingam, J. Sands, T. Jiang, S. Mukherjee, E. Anderson, B.C. Cho
Journal: Annals of Oncology (2023)
LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
Authors: J. Chan, S. Geyer, F-S. Ou, M. Knopp, S. Behr, T. Zemla, J. Acoba, A. Shergill, E.M. Wolin, T.R. Halfdanarson, N. Trikalinos, B. Konda, N. Vijayvergia, N.A. Dasari, J. Strosberg, E.C. Kohn, M.H. Kulke, E.M. O'Reilly, J.A. Meyerhardt
Journal: Annals of Oncology (2023)
LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial
Authors: B.J. van der Wilk, B.M. Eyck, B.P.L. Wijnhoven, S.M. Lagarde, C. Rosman, B.J. Noordman, M.J. Valkema, P-P. Coene, J-W. Dekker, H. Hartgrink, J. Heisterkamp, E. Kouwenhoven, G. Nieuwenhuijzen, J-P. Pierie, J. van Sandick, M. Sosef, M. Spaander, E. van der Zaag, E. Steyerberg, J. van Lanschot
Journal: Annals of Oncology (2023)
LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Authors: M.C. Garassino, J. Mazieres, M. Reck, C. Chouaid, H. Bischoff, N. Reinmuth, L.S. Cove-Smith, T. Mansy, D.L. Cortinovis, M.R. Migliorino, A. Delmonte, J. García Sanchez, L.E. Chara Velarde, R. Bernabe Caro, L. Paz-Ares, P. Chander, I. Diaz Perez, K. Foroutanpour, C. Faivre-Finn
Journal: Annals of Oncology (2023)
LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
Authors: Y. Nakahara, T. Kato, R. Isomura, T. Misumi, M. Tamiya, K. Yoh, N. Furuya, A. Ono, Y. Takiguchi, K. Koyama, S. Ikeda, K. Watanabe, T. Tokito, N. Seki, H. Imai, T. Shukuya, Y. Shibata, S. Hosokawa, T. Kozuki, H. Okamoto
Journal: Annals of Oncology (2023)
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
Authors: T.B. Powles, B. Perez Valderrama, S. Gupta, J. Bedke, E. Kikuchi, J. Hoffman-Censits, G. Iyer, C. Vulsteke, S.H. Park, S.J. Shin, D.E. Castellano Gauna, G. Fornarini, J-R. Li, M. Gumus, N. Mar, S. Narayanan, X. Yu, S. Gorla, B.M.S. Homet Moreno van der Heijden
Journal: Annals of Oncology (2023)
LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Authors: H.H.F. Loong, K. Goto, B.J. Solomon, K. Park, M. Pérol, E. Arriola, S. Novello, Y. Cheng, A. Ardizzoni, M. Mak, F.C. Santini, Y.Y. Elamin, A. Drilon, J. Wolf, B. Han, H. Han, M. Uh, T. Puri, V. Ilaria, C. Zhou
Journal: Annals of Oncology (2023)